Overview
Research shows that mice exposed to flickering lights and sounds experience a reduction in memory impairment associated with Alzheimer’s disease. The GARNET Study is investigating whether similar effects are experienced by humans.
This research effort is led by our Translational Research team and focuses on optimizing our technology. This study is not intended to treat Alzheimer’s disease. Participation is compensated.
Our Design
The GARNET Study aims to inform the development of a therapy for Alzheimer’s disease.
Sensory Stimulation
Feasibility Testing
Placebo Controlled
In-Office Visits
One to Three Visits, Two to Three Hours Each Visit
Participate
This survey will determine your eligibility for participation in our study. If you qualify, our team will reach out to provide additional details and next steps.
Compensation is provided if you are enrolled in any of our study visits.
Eligibility Criteria
Adults living in the Greater Boston area
55+ years old
Adults experiencing early symptoms of Alzheimer’s disease such as unclear thinking and memory loss
Our Approach
Alzheimer’s disease is a form of dementia characterized by the progressive increase of memory impairment. This disease is also associated with the build-up of sticky plaques and tangles of certain proteins in the brain (tau and beta-amyloid).
Research from MIT demonstrated that flickering lights and sounds can induce specific pattern of brain activity (neural oscillations). This research, conducted in mice, showed important effects on multiple aspects of Alzheimer’s (e.g., tau and amyloid reduction, and memory improvement).
The GARNET Study is translating this research for human application in order to develop a possible therapy for Alzheimer’s disease.
